Travere Therapeutics (NASDAQ:TVTX) is in focus after a fresh update tied to rare disease therapies, with market attention on ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company ...

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders ...

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents per share which beat the analyst consensus estimate of losses of 26 cents ...

HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Summit Therapeutics (SMMT) and Argenx Se (ARGX) with bullish sentiments. According to TipRanks.com, Azar ...

TransMedics Group, Inc. ("TransMedics") , a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the ...

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will ...

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big ...

The Second Circuit closed the books on a novel issue that arose after Evan Greebel was convicted of securities fraud—whether ...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...